A药品名称: B药品名称: B与A对换
 药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
A药品
B药品
详细
Fenoterol
Vitespen
The therapeutic efficacy of Vitespen can be decreased when used in combination with Carfilzomib.
Fenoterol
GI-5005
The therapeutic efficacy of GI-5005 can be decreased when used in combination with Carfilzomib.
Fenoterol
SRP 299
The therapeutic efficacy of SRP 299 can be decreased when used in combination with Carfilzomib.
Fenoterol
Rindopepimut
The therapeutic efficacy of Rindopepimut can be decreased when used in combination with Carfilzomib.
Fenoterol
INGN 225
The therapeutic efficacy of INGN 225 can be decreased when used in combination with Carfilzomib.
Fenoterol
PEV3A
The therapeutic efficacy of PEV3A can be decreased when used in combination with Carfilzomib.
Fenoterol
G17DT
The therapeutic efficacy of G17DT can be decreased when used in combination with Carfilzomib.
Fenoterol
Tofacitinib
Carfilzomib may increase the immunosuppressive activities of Tofacitinib.
Fenoterol
Naloxegol
The serum concentration of Naloxegol can be increased when it is combined with Carfilzomib.
Fenoterol
Ledipasvir
The serum concentration of Carfilzomib can be increased when it is combined with Ledipasvir.
Fenoterol
Edoxaban
The serum concentration of Edoxaban can be increased when it is combined with Carfilzomib.
Fenoterol
Afatinib
The serum concentration of Carfilzomib can be increased when it is combined with Afatinib.
Fenoterol
Methoxy polyethylene glycol-epoetin beta
The risk or severity of Thrombosis can be increased when Methoxy polyethylene glycol-epoetin beta is combined with Carfilzomib.
Fenoterol
Peginesatide
The risk or severity of Thrombosis can be increased when Peginesatide is combined with Carfilzomib.
Fenoterol
Sipuleucel-T
The therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Carfilzomib.
Fenoterol
Roflumilast
Roflumilast may increase the immunosuppressive activities of Carfilzomib.
Fenoterol
Difluocortolone
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Difluocortolone.
Fenoterol
Clobetasol
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Clobetasol.
Fenoterol
Fluocortolone
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Fluocortolone.
Fenoterol
Hydrocortisone butyrate
The risk or severity of adverse effects can be increased when Carfilzomib is combined with Hydrocortisone butyrate.
免责声明:以上所展示的信息由企业自行提供,内容的真实性、准确性和合法性由发布企业负责,医药网对此不承担任何责任。
相关链接:医药研究数据| 医药资料| SDA药品评审中心| 中医网| 中药处方系统| 爱视立眼贴
专业提供药品信息、药品招商、药品代理、保健品招商、医药原料采购供应的中国药品信息网站平台
版权所有 © 2003-2028 盗冒必究  客服热线:0575-83552251 / 13754370441  QQ客服:药品信息客服
浙ICP备16010490号-2 增值电信业务经营许可证:浙B2-20220931 互联网药品信息服务资格证书编号:(浙)-经营性2023-0215 浙公网安备:330683240604819103159
 医药代理商群1:药药网药品采购交流医药代理商群2:药药网药品采购交流2医药代理商群3:药药网药品采购交流3